Table 3.
Odds ratio (95% CI)* | p value | ||
---|---|---|---|
Age, per decade of life | 1·44 (1·31–1·57) | <0·001 | |
Sex | |||
Female | 1·00 (ref) | .. | |
Male | 1·38 (1·05–1·80) | 0·020 | |
Time period | |||
June 15, 2020, or before | 1·00 (ref) | .. | |
June 16, 2020, to Sept 30, 2020 | 0·80 (0·54–1·19) | 0·27 | |
Oct 1, 2020, to April 12, 2021 | 0·39 (0·30–0·51) | <0·001 | |
Number of comorbidities | 1·39 (1·23–1·58) | <0·001 | |
Smoking status | |||
Never smoker | 1·00 (ref) | .. | |
Ever smoker | 1·01 (0·70–1·46) | 0·95 | |
Body-mass index, mg/kg2 | |||
<30 | 1·00 (ref) | .. | |
≥30 | 1·07 (0·78–1·46) | 0·16 | |
Glucocorticoid (prednisolone equivalent) use, mg/day | |||
0 | 1·00 (ref) | .. | |
1–5 | 1·14 (0·83–1·57) | 0·41 | |
6–9 | 1·22 (0·75–1·97) | 0·43 | |
≥10 | 2·14 (1·50–3·04) | <0·001 | |
Disease activity | |||
Remission or low | 1·00 (ref) | .. | |
Moderate, or high or severe | 2·12 (1·49–3·02) | <0·001 |
This analysis excludes 182 patients with missing outcome data.
Adjusted for age, sex, time period, number of comorbidities, smoking status, obesity, glucocorticoid use, disease activity, region, and medication category.